Myelin peptides in multiple sclerosis

Autoimmunity Reviews

Volumn 8, Issue 8, 2009, Pages 650-653

  Grau Lopez L ^a,b   Raich D ^a,b   Ramo Tello, C ^a,b   Naranjo Gomez M ^a,b   Davalos A ^a,b   Pujol Borrell, R ^a,b   Borras F E ^a,b   Martinez Caceres E ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cell proliferation; Cell therapy; Multiple sclerosis; Myelin peptides; T cell reactivity

Indexed keywords

ANTIGEN; EPITOPE; MYELIN;

ALLERGIC ENCEPHALOMYELITIS; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MULTIPLE SCLEROSIS; NONHUMAN; PEPTIDE ANALYSIS; REVIEW; T LYMPHOCYTE;

ALPHA-CRYSTALLIN B CHAIN; ANIMALS; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELIN-ASSOCIATED GLYCOPROTEIN; PEPTIDES; S100 PROTEINS; TRANSALDOLASE;

EID: 67349090563     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.02.013     Document Type: Review

References (34)

1. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46 (1996) 907-911
2. Martin R., McFarland H.F., and McFarlin D.E. Immunological aspects of demyelinating diseases. Annu Rev Immunol 10 (1992) 153-187
3. Furuzawa-Carballeda J., Vargas-Rojas M.I., and Cabral A.R. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 6 (2007) 169-175
4. Hillert J., and Olerup O. HLA and multiple sclerosis. Neurology 43 (1993) 2426-2427
5. Zamvil S.S., and Steinman L. The T lymphocyte in EAE. Annu Rev Immunol 8 (1990) 579-621
6. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6 (2000) 1167-1175
7. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., and Linington C. Animal models. Ann Neurol 36 (1994) S47-53
8. Kojima K., Wekerle H., Lassmann H., Berger T., and Linington C. Induction of experimental autoimmune encephalomyelitis by CD4+ T cells specific for an astrocyte protein, S100 beta. J Neural Transm Suppl 49 (1997) 43-51
9. Schluessener H.J., and Wekerle H. Autoaggressive T lymphocite lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocite populations. J. Immunol 135 (1985) 3128-3133
10. Madsen L.S., Andersson E.C., Jansson L., Krogsgaard M., Andersen C.B., Engberg J., et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 23 (1999) 343-347
11. Pelfrey C.M., Trotter J.L., Tranquill L.R., and Mc Farland H.F. Identification of a novel T cell epitope of human proteolipid protein recognized by proliferative and cytolytic CD4+T cells from multiple sclerosis patients. J Neuroimmunol 46 (1993) 33-42
12. Bielekova B., Sung M.H., Kadom N., Simon R., Mc Farland H., and Martin R. Expansion and functional relevance of high avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol 172 (2004) 3893-3904
13. Weissert R., Kuhle J., de Graaf K.L., Wienhold W., Herrmann M.M., Müller C., et al. High immunogenicity of intracellular myelin oligodendrocyte glycoprotein epitopes. J Immunol 169 (2002) 548-556
14. Lindert R.B., Haase C.G., Brehm U., Linington C., Wekerle H., and Hohlfeld R. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 122 (1999) 2089-2100
15. Andersson M., Yu M., Soderstrom M., Weerth S., Baig S., Solders G., et al. Multiple MAG peptides are recognized by circulating T and B lymphocytes in polyneuropathy and multiple sclerosis. Eur J Neurol 9 (2002) 243-251
16. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 23 (2005) 683-747
17. Greer J., Csurhes A., Cameron K., Mc Combe P., Good M., and Pender M. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120 (1997) 1447-1460
18. Sáez-Torres I., Brieva L., Espejo C., Barrau M.A., Montalban X., and Martínez-Caceres E.M. Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse. Autoimmunity 35 (2002) 45-50
19. Martin R., Jaraquemada D., Flerlage M., Richart J., Whitaker E., Long O., et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 145 (1990) 540-548
20. Pette M., Fujita K., Kitze B., Whitaker J.N., Albert E., Kappos L., and Wekerle H. Myelin basic protein-specific T lymphocytes lines from MS and healthy individuals. Neurology 40 (1990) 1770-1776
21. Ota K., Matsui M., Milford E.L., Making G.A., Weiner H.L., and Hafler D.A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 346 (1990) 183-187
22. Lunemann J., Rückert S., Kern F., Wendling U., Van der Zee R., Volk H., and Zipp F. Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis. J Neurol 251 (2004) 1111-1120
23. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., et al. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 91 (1993) 616-628
24. Allegretta M., Nicklas J., Sriram S., and Albertini R. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 247 (1990) 718-721
25. Lovett-Racke A.E., Trotter J.L., Lauber J., Perrin P.J., June C.H., and Racke M.K. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients: a marker for activated/memory T cells. J Clin Invest 101 (1998) 725-730
26. Scholz C., Patton K.T., Anderson D.E., Freeman G.J., and Hafler D.A. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 160 (1998) 1532-1538
27. Ucelli A., Giunti D., Salvetti M., Ristori G., Fenoglio D., et al. A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis patients. Clin Exp Immunol 111 (1998) 186-192
28. Schrempf W., and Ziemssen T. Glatiramer acetate: mechanisms of action in multiple sclerosis. Autoimmun Rev 6 (2007) 469-475
29. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
30. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The multiple sclerosis collaborative research group (MSCRG). Ann Neurol 39 (1996) 285-294
31. PRISMS (Prevention of relapses and disability by interferonβ-1a subcutaneously in multiple sclerosis) study group. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352 (1998) 1498-1504
32. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double blind placebo-controlled trial. Neurology 45 (1995) 1268-1276
33. Miller S.D., Turley D.M., and Podojil J.R. Tolerance induction to different autoantigens is a promising therapeutic strategy in autoimmune diseases. Nat Rev Immunol 7 (2007) 665-677
34. Correale J., Farez M., and Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs 22 (2008) 175-198